Chapter 9 - Hepatic Stellate Cells and Liver Cancer

Stellate Cells in Health and Disease

Volumn , Issue , 2015, Pages 145-162

  Dapito, Dianne H ^a   Schwabe, Robert F ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Extracellular matrix; Hepatic stellate cells; Hepatocellular carcinoma; Liver fibrosis

Indexed keywords

EID: 84940100341     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-800134-9.00009-9     Document Type: Chapter

References (91)

1. Luedde T, Kaplowitz N, Schwabe RF Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014, 147(4):765-783. e4.
2. Fattovich G, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5 Suppl. 1):S35-S50.
3. Hoshida Y, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359(19):1995-2004.
4. Hernandez-Gea V, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013, 144(3):512-527.
5. Luedde T, Schwabe RF NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011, 8(2):108-118.
6. Grivennikov SI, Greten FR, Karin M Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
7. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
8. Taura K, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008, 135(5):1729-1738.
9. Ehling J, et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014.
10. Mederacke I, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013, 4:2823.
11. Bissell MJ, Hines WC Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011, 17(3):320-329.
12. Olumi AF, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59(19):5002-5011.
13. Bhowmick NA, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303(5659):848-851.
14. Xu J, et al. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front Pharmacol 2014, 5:167.
15. Bakiri L, Wagner EF Mouse models for liver cancer. Mol Oncol 2013, 7(2):206-223.
16. Caviglia JM, Schwabe RF Experimental hepatocarcinogenesis. Pathobiology of Human Disease 2014, 1866-1880. Elsevier, San Diego. L.M. McManus, R.N. Mitchell (Eds.).
17. Bettermann K, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010, 17(5):481-496.
18. Inokuchi S, et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci USA 2010, 107(2):844-849.
19. Luedde T, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11(2):119-132.
20. Campbell JS, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005, 102(9):3389-3394.
21. Wright JH, et al. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. Int J Cancer 2014, 134(4):778-788.
22. Okada H, et al. Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res 2012, 72(17):4459-4471.
23. Hede SM, et al. GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background. Glia 2009, 57(11):1143-1153.
24. Fuchs BC, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 2014, 59(4):1577-1590.
25. Chau KY, et al. Myofibroblasts in hepatitis B related cirrhosis and hepatocellular carcinoma. J Clin Pathol 1992, 45(5):446-448.
26. Enzan H, et al. Alpha-smooth muscle actin-positive perisinusoidal stromal cells in human hepatocellular carcinoma. Hepatology 1994, 19(4):895-903.
27. Faouzi S, et al. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J Hepatol 1999, 30(2):275-284.
28. Ooi LPJ, et al. Evidence that "myofibroblast-like" cells are the cellular source of capsular collage in hepatocellular carcinoma. J Hepatol 1997, 26(4):798-807.
29. Ju MJ, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol 2009, 131(4):498-510.
30. Okabe H, et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009, 16(9):2555-2564.
31. Worthley DL, et al. Bone marrow cells as precursors of the tumor stroma. Exp Cell Res 2013.
32. Barcellos-de-Souza P, et al. Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim Biophys Acta 2013, 1836(2):321-335.
33. Mishra PJ, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008, 68(11):4331-4339.
34. Quante M, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19(2):257-272.
35. Amann T, et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009, 100(4):646-653.
36. Wang ZM, et al. Rat hepatic stellate cells alter the gene expression profile and promote the growth, migration and invasion of hepatocellular carcinoma cells. Mol Med Rep 2014.
37. Coulouarn C, et al. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012, 72(10):2533-2542.
38. Mikula M, et al. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol 2006, 209(2):560-567.
39. Geng ZM, et al. Activated human hepatic stellate cells promote growth of human hepatocellular carcinoma in a subcutaneous xenograft nude mouse model. Cell Biochem Biophys 2014, 70(1):337-347.
40. Lin N, et al. Role of activated hepatic stellate cells in proliferation and metastasis of hepatocellular carcinoma. Hepatol Res 2014.
41. Hynes RO The extracellular matrix: not just pretty fibrils. Science 2009, 326(5957):1216-1219.
42. Rombouts K, Carloni V The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma. Fibrogenesis Tissue Repair 2013, 6(1):17.
43. Carloni V, Luong TV, Rombouts K Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int 2014, 34(6):834-843.
44. Santamato A, et al. Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clin Sci (Lond) 2011, 121(4):159-168.
45. Lai KK, et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 2011, 7(6):e1002147.
46. Lee SK, et al. Integrin alpha V polymorphisms and haplotypes in a Korean population are associated with susceptibility to chronic hepatitis and hepatocellular carcinoma. Liver Int 2009, 29(2):187-195.
47. Cox D, Brennan M, Moran N Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010, 9(10):804-820.
48. Zhang DY, Friedman SL Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012, 56(2):769-775.
49. Levental KR, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139(5):891-906.
50. Lu P, Weaver VM, Werb Z The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196(4):395-406.
51. Schrader J, et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 2011, 53(4):1192-1205.
52. Zhao W, et al. Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab Invest 2014, 94(2):182-191.
53. Masuzaki R, et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol 2008, 42(7):839-843.
54. Begum NA, et al. Differential display and integrin alpha 6 messenger RNA overexpression in hepatocellular carcinoma. Hepatology 1995, 22(5):1447-1455.
55. Zhao G, et al. Mechanical stiffness of liver tissues in relation to integrin beta1 expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma. J Surg Oncol 2010, 102(5):482-489.
56. Giannelli G, et al. Altered expression of integrins and basement membrane proteins in malignant and pre-malignant lesions of oral mucosa. J Biol Regul Homeost Agents 2001, 15(4):375-380.
57. Okazaki I Novel cancer-targeting agents/application strategies developed from MMP science. Anticancer Agents Med Chem 2012.
58. Jia YL, et al. Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis. Hepatology 2011, 54(5):1808-1818.
59. Kang N, Gores GJ, Shah VH Hepatic stellate cells: partners in crime for liver metastases?. Hepatology 2011, 54(2):707-713.
60. Zhao W, et al. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer 2011, 129(11):2651-2661.
61. Zhao W, et al. The role of hepatic stellate cells in the regulation of T-cell function and the promotion of hepatocellular carcinoma. Int J Oncol 2012, 41(2):457-464.
62. Rosmorduc O, Housset C Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010, 30(03):258-270.
63. Ankoma-Sey V, Wang Y, Dai Z Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 2000, 31(1):141-148.
64. Sanz-Cameno P, et al. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol 2006, 169(4):1215-1222.
65. Torimura T, et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol 2004, 40(5):799-807.
66. Olaso E, et al. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 2003, 37(3):674-685.
67. Kang N, et al. Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth. Am J Pathol 2010, 177(4):1888-1900.
68. Chen JA, et al. Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int 2010, 4(3):537-547.
69. Zhang ZL, Liu ZS, Sun Q Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2006, 12(26):4241-4245.
70. Wirz W, et al. Hepatic stellate cells display a functional vascular smooth muscle cell phenotype in a three-dimensional co-culture model with endothelial cells. Differentiation 2008, 76(7):784-794.
71. Shimizu S, et al. In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn J Cancer Res 2000, 91(12):1285-1295.
72. Meindl-Beinker NM, Matsuzaki K, Dooley S TGF-beta signaling in onset and progression of hepatocellular carcinoma. Dig Dis 2012, 30(5):514-523.
73. Stover DG, Bierie B, Moses HL A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem 2007, 101(4):851-861.
74. Dapito DH, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21(4):504-516.
75. Ljubimova JY, et al. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 1997, 45(1):79-87.
76. Neaud V, et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 1997, 26(6):1458-1466.
77. Riese Ii DJ, Cullum RL Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol 2014, 28:49-56.
78. Neufert C, et al. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest 2013, 123(4):1428-1443.
79. Zhao M, et al. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochem Biophys Res Commun 2009, 387(2):239-244.
80. Brandl K, et al. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci USA 2010, 107(46):19967-19972.
81. Shirasawa S, et al. Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage. Proc Natl Acad Sci USA 2004, 101(38):13921-13926.
82. Zhang Y, et al. Important role of epiregulin in inflammatory responses during corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2012, 53(4):2414-2423.
83. Lujambio A, et al. Non-cell-autonomous tumor suppression by p53. Cell 2013, 153(2):449-460.
84. Yoshimoto S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499(7456):97-101.
85. Wright MC, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001, 121(3):685-698.
86. Horie T, et al. L-cysteine administration prevents liver fibrosis by suppressing hepatic stellate cell proliferation and activation. Biochem Biophys Res Commun 2003, 305(1):94-100.
87. Yin C, et al. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest 2013, 123(5):1902-1910.
88. Bansal R, et al. Targeted recombinant fusion proteins of IFNgamma and mimetic IFNgamma with PDGFbetaR bicyclic peptide inhibits liver fibrogenesis in vivo. PLoS One 2014, 9(2):e89878.
89. Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390.
90. Mejias M, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009, 49(4):1245-1256.
91. Hennenberg M, et al. Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest 2011, 91(2):241-251.